F/M Investments’s Moderna MRNA Stock Holding History

F/M Investments’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,171	Closed	-$1.58M	–	93
2020 Q4	$1.58M	Buy	+15,171	New	+$1.53M	1.38%	30

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

F/M Investments's MRNA Position: Q1 2021 in Review

F/M Investments sold out of Moderna (MRNA) in Q1 2021, closing a stake of 15,171 shares — an estimated $1.58M sold.

F/M Investments first reported a position in MRNA in Q4 2020 and held it in 1 quarter. The position peaked at $1.58M in Q4 2020. 776 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

F/M Investments reported no remaining Moderna position as of Q1 2021 after selling out during the quarter.
F/M Investments sold 15,171 Moderna shares in Q1 2021, an estimated $1.58M.
F/M Investments first reported a position in Moderna in Q4 2020 and held it in 1 quarter.
F/M Investments's Moderna position peaked at $1.58M in Q4 2020.
776 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on F/M Investments's 13F filing for Q1 2021, filed 1 Jun 2021.